TY - JOUR
T1 - Microtube Array Membrane Encapsulated Cell Therapy
T2 - A Novel Platform Technology Solution for Treatment of Alzheimer’s Disease
AU - Hsu, Tsung Chin
AU - Chew, Chee Ho
AU - Chen, Shu Mei
AU - Huang, Wan Ting
AU - Chen, Amanda Lin
AU - Lin, Yung Feng
AU - Eddarkaoui, Sabiha
AU - Buee, Luc
AU - Chen, Chien Chung
N1 - Funding Information:
Funding: International Laboratory funding scheme (NeuroTMULille) is supported by the University of Lille and TMU. This research was funded by Programmes d’Investissements d’Avenir LabEx (excellence laboratory), DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to Alzheimer’s disease).
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Alzheimer’s disease is the most frequent form of dementia in aging population and is presently the world’s sixth largest cause of mortality. With the advancement of therapies, several solutions have been developed such as passive immunotherapy against these misfolded proteins, thereby resulting in the clearance. Within this segment, encapsulated cell therapy (ECT) solutions that utilize antibody releasing cells have been proposed with a multitude of techniques under de-velopment. Hence, in this study, we utilized our novel and patented Microtube Array Membranes (MTAMs) as an encapsulating platform system with anti-pTau antibody-secreting hybridoma cells to study the impact of it on Alzheimer’s disease. In vivo results revealed that in the water maze, the mice implanted with hybridoma cell MTAMs intracranially (IN) and subcutaneously (SC) showed improvement in the time spent the goal quadrant and escape latency. In passive avoidance, hybrid-oma cell loaded MTAMs (IN and SC) performed significantly well in step-through latency. At the end of treatment, animals with hybridoma cell loaded MTAMs had lower phosphorylated tau (pTau) expression than empty MTAMs had. Combining both experimental results unveiled that the clearance of phosphorylated tau might rescue the cognitive impairment associated with AD.
AB - Alzheimer’s disease is the most frequent form of dementia in aging population and is presently the world’s sixth largest cause of mortality. With the advancement of therapies, several solutions have been developed such as passive immunotherapy against these misfolded proteins, thereby resulting in the clearance. Within this segment, encapsulated cell therapy (ECT) solutions that utilize antibody releasing cells have been proposed with a multitude of techniques under de-velopment. Hence, in this study, we utilized our novel and patented Microtube Array Membranes (MTAMs) as an encapsulating platform system with anti-pTau antibody-secreting hybridoma cells to study the impact of it on Alzheimer’s disease. In vivo results revealed that in the water maze, the mice implanted with hybridoma cell MTAMs intracranially (IN) and subcutaneously (SC) showed improvement in the time spent the goal quadrant and escape latency. In passive avoidance, hybrid-oma cell loaded MTAMs (IN and SC) performed significantly well in step-through latency. At the end of treatment, animals with hybridoma cell loaded MTAMs had lower phosphorylated tau (pTau) expression than empty MTAMs had. Combining both experimental results unveiled that the clearance of phosphorylated tau might rescue the cognitive impairment associated with AD.
KW - Alzheimer’s disease (AD)
KW - encapsulated cell therapy
KW - microtube array membrane (MTAMs)
KW - neurodegenerative disease
KW - passive immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85132201725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132201725&partnerID=8YFLogxK
U2 - 10.3390/ijms23126855
DO - 10.3390/ijms23126855
M3 - Article
C2 - 35743295
AN - SCOPUS:85132201725
SN - 1661-6596
VL - 23
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 12
M1 - 6855
ER -